LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Sorafenib | 0.04 | uM | LJP6 | 3 | B12 | 72 | hr | 1401 | 3981 | 4272 | 0.9318 | 0.9141 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 1 | B11 | 72 | hr | 1401 | 3938 | 4139 | 0.9514 | 0.9373 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 2 | B11 | 72 | hr | 1401 | 4229 | 4095 | 1.0326 | 1.0419 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 3 | B11 | 72 | hr | 1401 | 3962 | 4272 | 0.9274 | 0.9084 |
| SK-BR-3 | Sorafenib | 0.37 | uM | LJP6 | 1 | B10 | 72 | hr | 1401 | 4259 | 4139 | 1.0290 | 1.0369 |
| SK-BR-3 | Sorafenib | 0.37 | uM | LJP6 | 2 | B10 | 72 | hr | 1401 | 4237 | 4095 | 1.0346 | 1.0444 |
| SK-BR-3 | Sorafenib | 0.37 | uM | LJP6 | 3 | B10 | 72 | hr | 1401 | 4074 | 4272 | 0.9536 | 0.9417 |
| SK-BR-3 | Sorafenib | 1.11 | uM | LJP6 | 1 | B09 | 72 | hr | 1401 | 4078 | 4139 | 0.9853 | 0.9811 |
| SK-BR-3 | Sorafenib | 1.11 | uM | LJP6 | 2 | B09 | 72 | hr | 1401 | 3919 | 4095 | 0.9569 | 0.9439 |
| SK-BR-3 | Sorafenib | 1.11 | uM | LJP6 | 3 | B09 | 72 | hr | 1401 | 4325 | 4272 | 1.0123 | 1.0153 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 1 | B08 | 72 | hr | 1401 | 4352 | 4139 | 1.0515 | 1.0653 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 2 | B08 | 72 | hr | 1401 | 4353 | 4095 | 1.0629 | 1.0805 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 3 | B08 | 72 | hr | 1401 | 4352 | 4272 | 1.0186 | 1.0231 |
| SK-BR-3 | Sorafenib | 10 | uM | LJP6 | 1 | B07 | 72 | hr | 1401 | 2631 | 4139 | 0.6357 | 0.4965 |
| SK-BR-3 | Sorafenib | 10 | uM | LJP6 | 2 | B07 | 72 | hr | 1401 | 2913 | 4095 | 0.7113 | 0.6047 |
| SK-BR-3 | Sorafenib | 10 | uM | LJP6 | 3 | B07 | 72 | hr | 1401 | 2536 | 4272 | 0.5936 | 0.4460 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 1 | I12 | 72 | hr | 1401 | 5290 | 3978 | 1.3296 | 1.4167 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 2 | I12 | 72 | hr | 1401 | 4625 | 4213 | 1.0977 | 1.1209 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 3 | I12 | 72 | hr | 1401 | 4675 | 4545 | 1.0284 | 1.0333 |
| SK-BR-3 | CP466722 | 0.12 | uM | LJP5 | 1 | I11 | 72 | hr | 1401 | 5014 | 3978 | 1.2603 | 1.3322 |
| SK-BR-3 | CP466722 | 0.12 | uM | LJP5 | 2 | I11 | 72 | hr | 1401 | 3867 | 4213 | 0.9178 | 0.8949 |
| SK-BR-3 | CP466722 | 0.12 | uM | LJP5 | 3 | I11 | 72 | hr | 1401 | 4017 | 4545 | 0.8837 | 0.8595 |
| SK-BR-3 | CP466722 | 0.37 | uM | LJP5 | 1 | I10 | 72 | hr | 1401 | 5159 | 3978 | 1.2967 | 1.3768 |
| SK-BR-3 | CP466722 | 0.37 | uM | LJP5 | 2 | I10 | 72 | hr | 1401 | 4156 | 4213 | 0.9864 | 0.9828 |
| SK-BR-3 | CP466722 | 0.37 | uM | LJP5 | 3 | I10 | 72 | hr | 1401 | 4525 | 4545 | 0.9954 | 0.9946 |